These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35444949)

  • 1. Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study.
    Yu J; Wang Z; Li Z; Liu Y; Fan Y; Di J; Cui M; Xing J; Zhang C; Yang H; Yao Z; Zhang N; Chen L; Liu M; Xu K; Tan F; Gao P; Su X
    Front Oncol; 2022; 12():853337. PubMed ID: 35444949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: a propensity score-matched cohort study.
    Yu J; Wang Z; Yang H; Zhang C; Xing J; Cui M; Liu H; Wu Y; Su X
    Int J Surg; 2023 Nov; 109(11):3283-3293. PubMed ID: 37526103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study.
    Ren DF; Zheng FC; Zhao JH; Shen GS; Ahmad R; Zhang SS; Zhang Y; Kan J; Dong L; Wang ZY; Zhao FX; Zhao JD
    World J Clin Cases; 2018 Sep; 6(10):373-383. PubMed ID: 30283800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection.
    Yu Y; Zhang Z; Meng Q; Ma Y; Fan X; Sun J; Wang G
    Front Oncol; 2021; 11():684627. PubMed ID: 34109131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Chemotherapy With S-1 Plus Docetaxel
    Yamamoto M; Omori T; Shinno N; Hara H; Mukai Y; Sugase T; Takeoka T; Mikamori M; Kanemura T; Hasegawa S; Akita H; Haraguchi N; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H; Ohue M
    Anticancer Res; 2023 Nov; 43(11):5015-5024. PubMed ID: 37909962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients.
    Yu S; Wang Y; Cheng X; Lv M; Cui Y; Li W; Yu Y; Li Q; Liu T
    Cancer Manag Res; 2020; 12():10091-10101. PubMed ID: 33116865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
    BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).
    Satake H; Miki A; Kondo M; Kotake T; Okita Y; Hatachi Y; Yasui H; Imai Y; Ichikawa C; Murotani K; Hashida H; Kobayashi H; Kotaka M; Kato T; Kaihara S; Tsuji A
    ESMO Open; 2017; 2(1):e000130. PubMed ID: 28761726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
    Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C
    JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
    Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
    Wang Z; He T; Yu D; Qin X; Geng A; Yang H
    Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review.
    Sugawara K; Kawaguchi Y; Seto Y; Vauthey JN
    Surg Oncol; 2021 Sep; 38():101599. PubMed ID: 33991939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
    Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
    Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
    Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
    Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.